Comparison · NCT04391309-sae
IC14 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IC14 vs Placebo: serious adverse events. Trial comparisons, record NCT04391309-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04391309-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.2 | 0.0807 | 0.416 | wilson | |
| Risk in group 2 | 0.05 | 0.00888 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | 0.15 | -0.0711 | 0.37 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4 | 0.489 | 32.7 | log | |
| Odds ratio, group 1 over group 2 | 4.75 | 0.481 | 46.9 | log | |
| Number needed to harm, for one more participant with a serious adverse event on IC14 than on Placebo | 6.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IC14 | Subjects received IC14 4 mg/kg intravenously on Day 1, followed by IC14 2 mg/kg/day intravenously on Days 2-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). | 4 | 20 | EG000 |
| Group 2 | Placebo | Subjects received 0.9% w/v Sodium Chloride in a matching bag and volume administered intravenously daily on Days 1-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). | 1 | 20 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 0 - Day 60
Source ClinicalTrials.gov
Trial
- Title
- COVID-19 and Anti-CD14 Treatment Trial
- NCT number
- NCT04391309
- Phases
- PHASE2
- Conditions
- Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Interventions
- anti-CD14, Placebo, remdesivir
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2023-06-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04391309?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04391309-sae